(Q36817176)

16 August 2017

1 reference

title

Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole (English)

1 reference

16 August 2017

Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole (English)

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)62479-3

15 November 2022

1 reference

1 reference

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1749296

15 November 2022

author name string

J. D. Smilack

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1749296

15 November 2022

W. R. Wilson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1749296

15 November 2022

F. R. Cockerill

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1749296

15 November 2022

language of work or name

English

0 references

publication date

1 December 1991

1 reference

full work available at URL

16 August 2017

https://api.elsevier.com/content/article/PII:S0025619612624793?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)62479-3

https://api.elsevier.com/content/article/PII:S0025619612624793?httpAccept=text/plain

15 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)62479-3

15 November 2022

1 reference

16 August 2017

66

1 reference

16 August 2017

12

1 reference

16 August 2017

1270-1280

1 reference

The Mode of Action of Antibiotics on Gram-Negative Bacilli

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Shedding ofMycoplasma pneumoniaeafter Tetracycline and Erythromycin Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Prophylactic doxycycline for travelers' diarrhea. Results of a prospective double-blind study of Peace Corps volunteers in Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Treatment of the acute urethral syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Interference of Iron with the Absorption of Tetracylines in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Side effects of minocycline: a double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Methoxyflurane, Tetracycline, and Renal Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Chloramphenicol: A review of its use in clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Antimicrobial susceptibilities of anaerobic bacteria isolated at the Mayo Clinic during 1982 through 1987: comparison with results from 1977 through 1981.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

The bacterial degradation of chloramphenicol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

7 January 2021

Campylobacter enteritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

COMPARISON OF THE BLOOD LEVELS OBTAINED AFTER SINGLE AND MULTIPLE DOSES OF ERYTHROMYCIN ESTOLATE AND ERYTHROMYCIN STEARATE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Reversible sensorineural hearing loss with intravenous erythromycin lactobionate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Clindamycin: a review of fifteen years of experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

The development of antimicrobial resistance in staphylococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Therapeutic implications of bacteriologic findings in mixed aerobic-anaerobic infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Clindamycin compared with penicillin for the treatment of anaerobic lung abscess

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

An open study of the pyrimethamine-clindamycin combination in AIDS patients with brain toxoplasmosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Clindamycin with primaquine for Pneumocystis carinii pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Clindamycin/primaquine for Pneumocystis carinii pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Clostridium difficile: clinical considerations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Disease associated with Clostridium difficile infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Clostridium difficile: its disease and toxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Susceptibility of anaerobic bacteria to 23 antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962479-3

Antimicrobial spectrum, pharmacology, and therapeutic use of antibiotics. IV. Aminoglycosides

7 January 2021

10

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)62479-3

Clindamycin and quinine treatment for Babesia microti infections

15 November 2022

33

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)62479-3

Metronidazole in the treatment of anaerobic infections

15 November 2022

51

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)62479-3

Topical metronidazole for rosacea

15 November 2022

53

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)62479-3

15 November 2022

Identifiers

1 reference

16 August 2017

1 reference